2026· [Rinsho ketsueki] The Japanese journal of clinical hematology· Vol 67 8, pp.
896-901
· 0 citations
Medicine
TL;DR
This case highlights the importance of considering AA in the differential diagnosis of persistent thrombocytopenia or pancytopenia during immune checkpoint inhibitor therapy, and reports of AA induced by durvalumab are extremely limited.
Thymoma resection may reduce immune attack on the bone marrow and create conditions favorable for hematopoietic recovery by removing the source of continued generation and export of abnormal T cells; however, abnormal T cells that have already entered the peripheral blood or bone marrow and continue to survive may perp...
An Wang, Yu Xia, Meng-Yuan Xin et al.· Frontiers in Oncology· 0 citations
Acute undifferentiated leukemia (AUL) is a rare, highly aggressive hematologic malignancy with a dismal prognosis and no standardized first-line treatment. Conventional acute myeloid leukemia (AML)-type or acute lymphoblastic leukemia (ALL)-type chemotherapy yields low remission rates, and most patients fail to achie...
Cheng Cheng, Rui-Hua Mi, Dong-Bei Li et al.· Annals of Hematology· 0 citations
How reliance on blast morphology alone in this context could be misleading is illustrated and the importance of integrating flow cytometry with other laboratory modalities to classify such complex malignancies and guide subsequent therapy is highlighted, highlighting therapy-related leukaemogenesis in survivors of this...
Iptacopan served as a bridge to control hemolysis, while the subsequent addition of IST addressed the underlying autoimmune bone marrow failure and no breakthrough hemolysis, extravascular hemolysis, or drug-related adverse events were observed.
Xiao-Qian Liu, Jie Xu, Ya-Qin Luo et al.· Medicine· 0 citations
We report the case of a 69-year-old woman with metastatic lung adenocarcinoma who developed severe thrombotic microangiopathy (TMA) only seven days after receiving her first dose of gemcitabine. The patient had pre-existing stage 3a chronic kidney disease and previous exposure to bevacizumab, which may have increased h...
S. Badaoui, M. Bouchoual, S. Anibar et al.· SAS Journal of Medicine· 0 citations
As pembrolizumab has been widely used in the immunotherapy of various solid tumors such as melanoma and lung cancer, reports of pembrolizumab-related adverse drug events have gradually attracted attention; however, cases of pembrolizumab-induced fulminant type 1 diabetes mellitus (FT1DM) remain rare. This article repor...
Shu-Jun Sun, Liang Su, Xiao-Jing Ma et al.· Frontiers in Endocrinology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.